Category:

Release – Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TNXP

May 29, 2024 8:00am EDT

Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital

CHATHAM, N.J., May 29, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced two oral presentations and a poster presentation at the American Transplant Congress 2024, being held June 1-5, 2024 at the Pennsylvania Convention Center, Philadelphia, Pa. Details on each presentation can be found below.

Copies of the Company’s poster presentations will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the American Transplant Congress website here.

Oral Presentations Details
Presenter: Kohei Kinoshita, M.D., Center for Transplantation Sciences, Massachusetts General Hospital
Title: Combined Blockade of the CD154 and CD28 Co-Stimulation Pathways Attenuates Pathogenic Alloimmunity and Prolongs Survival in Cynomolgus Cardiac Allografts
Location: 109-AB‚ Level 1
Abstract: 860
Date/Time: Tuesday, June 4, 2024, 9:45 a.m. ET
   
Presenter: Ikechukwu Ileka, M.D., Massachusetts General Hospital and Harvard Medical School
Title: Extended Survival of 9- and 10-Gene-Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade-Based Immunosuppression
Location: 114 – Nutter Theater‚ Level 1
Abstract: 932
Date/Time: Tuesday, June 4, 2024, 10:15 a.m. ET
   
Poster Presentations Details
Presenter: Ikechukwu Ileka, M.D., Massachusetts General Hospital and Harvard Medical School
Title: Experience with a Novel Delayed Immune Tolerance Protocol in Nonhuman Primates Based on Anti-CD154, Anti-CD2, and Anti-CD28
Location: Poster Hall‚ Exhibit Hall A‚ Level 2
Abstract: C086
Date/Time: Monday, June 3, 2024, 9:15 a.m. ET
   

Tonix Pharmaceuticals Holding Corp.*

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya1, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

1Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Media Contact

Katie Dodge
LaVoieHealthScience
kdodge@lavoiehealthscience.com
(978) 360-3151

Primary Logo

Source:

Released May 29, 2024

Release – Alliance Resource Partners, L.P. Announces Private Offering of Senior Notes

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ARLP

May 29, 2024

Download(opens in new window)

TULSA, Okla.–(BUSINESS WIRE)– Alliance Resource Partners, L.P. (NASDAQ: ARLP) (“ARLP”) announced today that Alliance Resource Operating Partners, L.P. (“AROP”), the intermediate partnership of ARLP, and AROP’s wholly owned subsidiary, Alliance Resource Finance Corporation, subject to market conditions, intend to offer $400 million in aggregate principal amount of senior unsecured notes due 2029 (the “New Notes”) in a private placement to eligible purchasers.

AROP expects to use a portion of the net proceeds from the offering of the New Notes to fund the redemption of its outstanding 7.5% Senior Notes due 2025 (the “2025 Notes”) and the remaining for general corporate purposes. On May 29, 2024, AROP delivered a conditional notice of redemption, subject to consummation of the offering of the New Notes, for all of the outstanding 2025 Notes. The redemption price for the 2025 Notes is 100% of the principal amount of the 2025 Notes outstanding, plus accrued and unpaid interest to the redemption date, which is expected to be June 28, 2024. This communication shall not constitute a notice of redemption under the indenture governing the 2025 Notes.

The New Notes have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any other jurisdiction. Thus, the New Notes may be offered only in transactions that are exempt from registration under the Securities Act and applicable state securities laws. The New Notes are offered only to qualified institutional buyers under Rule 144A and to persons outside the United States under Regulation S of the Securities Act. The New Notes will not be listed on any securities exchange or automated quotation system.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the New Notes, nor shall there be any sale of the New Notes in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Alliance Resource Partners, L.P.

ARLP is a diversified energy company that is currently the largest coal producer in the eastern United States, supplying reliable, affordable energy domestically and internationally to major utilities, metallurgical and industrial users. ARLP also generates operating and royalty income from mineral interests it owns in strategic coal and oil & gas producing regions in the United States. In addition, ARLP is evolving and positioning itself as a reliable energy partner for the future by pursuing opportunities that support the advancement of energy and related infrastructure.

Cautionary Note Concerning Forward-Looking Statements

Certain statements and information in this news release constitute “forward-looking statements,” including statements regarding the intended use of proceeds. The words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could” or other similar expressions are intended to identify forward-looking statements, which are generally not historical in nature. These forward-looking statements represent ARLP’s expectations or beliefs concerning future events, and it is possible that the results described in this news release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of ARLP’s control, which could cause actual results to differ materially from the results discussed in the forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, ARLP does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for ARLP to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements found in ARLP’s filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, ARLP’s Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The risk factors and other factors noted in ARLP’s SEC filings could cause actual results to differ materially from those contained in any forward-looking statement.

Investor Relations Contact:

Cary P. Marshall

Senior Vice President and Chief Financial Officer

918-295-7673

investorrelations@arlp.com

Source: Alliance Resource Partners, L.P.

Wall Street Under Pressure as Fed Rate Uncertainty Weighs

Posted on by slightbourne@noblecapitalmarkets.com

Investors were squarely focused on the Federal Reserve’s next moves on interest rates as Wall Street kicked off the new week on a sour note. The major indexes pulled back on Wednesday, with the Dow Jones Industrial Average sliding nearly 1% to its lowest level in nearly a month.

The culprit? Rising Treasury yields across the board as expectations get muddled on when exactly the Fed will start cutting rates and by how much. The yield on the 10-year Treasury note climbed to a four-week high after an unexpectedly strong reading on U.S. consumer confidence.

This hits right at the heart of the stock market’s biggest preoccupation of late – will the Fed’s rate hiking campaign successfully tame inflation without severely denting economic growth? The conflicting signals have investors scratching their heads and selling stocks.

The tech-heavy Nasdaq retreated from Tuesday’s milestone close above 17,000, with pressure on megacap names like Microsoft, Alphabet, and Meta. The semiconductor index, a recent leadership group, dropped nearly 2%. Small-caps also got hit hard as the Russell 2000 fell over 1%.

Treasury yields climbing is a negative for valuations, especially in richly-valued sectors like tech. The CBOE Volatility Index (VIX), Wall Street’s fear gauge, spiked to its highest level since early May as rate concerns contributed to the market’s unease.

Investors began 2023 pricing in rate cuts as early as March, but sticky inflation readings and hawkish Fed rhetoric have walked back those expectations. According to the CME’s FedWatch Tool, traders are now only betting on a 25 basis point cut by November or December at the earliest.

The Fed’s “Beige Book” released Wednesday afternoon provided little clarity, depicting an economy expanding at a modest pace with elevated price pressures. Traders are now laser-focused on Friday’s Personal Consumption Expenditures (PCE) data, which is the Fed’s favored inflation metric.

Amid the cross-currents, there were pockets of strength driven by solid corporate news. Marathon Oil surged 8.7% after ConocoPhillips announced a $15 billion all-stock acquisition of the energy firm. DICK’S Sporting Goods and Abercrombie & Fitch also rallied double-digits after boosting their annual guidance.

But the broader market sold off, with declines across all eleven S&P 500 sectors. The airline industry was a notable laggard, with an airline stocks index tanking over 4% after American Airlines slashed its profit forecast.

For now, uncertainty continues to breed anxiety on Wall Street as investors attempt to gauge whether the Fed can orchestrate a long-hoped-for “soft landing” or if more turbulence is in store. All eyes will be laser-focused on upcoming inflation data and Fed speak for further clues on the path forward for interest rates.

Want small cap opportunities delivered straight to your inbox?

Channelchek’s free newsletter will give you exclusive access to our expert research, news, and insights to help you make informed investment decisions.

Get Instant Access

Unicycive Therapeutics (UNCY) – Data Presentations For OLC and UNI-494 Trials Presented

Posted on by cpereira@noblefcm.com


Wednesday, May 29, 2024

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Data From Both Products Shows Clinical Progress. Unicycive presented data at the European Renal Association (ERA) Congress for OLC and UNI-494, its two products currently in clinical development. Earlier this month, the company presented data from its OLC bioequivalence study and a market survey study on phosphate binder compliance at the National Kidney Foundation Spring Clinical Meeting.

OLC Clinical Data Presented At National Kidney Foundation Meeting. Unicycive presented data from its Phase 1 bioequivalence study comparing OLC with lanthanum carbonate, the active compound in the phosphate binder Fosrenol. The second poster presented data from a survey of renal dieticians who help manage patients’ diet and phosphate levels. The survey is consistent with prior data showing that daily pill burden is a factor in patient compliance, and that OLC’s reduced pill burden could lead to better compliance and patient outcomes. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Resources Connection (RGP) – Poised to Capitalize on a New Paradigm

Posted on by cpereira@noblefcm.com


Wednesday, May 29, 2024

Resources Connection, Inc. provides agile consulting services in North America, Europe, and the Asia Pacific. The company offers finance and accounting services, including process transformation and optimization, financial reporting and analysis, technical and operational accounting, merger and acquisition due diligence and integration, audit readiness, preparation and response, implementation of new accounting standards, and remediation support. It also provides information management services, such as program and project management, business and technology integration, data strategy, and business performance management. In addition, the company offers corporate advisory, strategic communications, and restructuring services; and corporate governance, risk, and compliance management services, such as contract and regulatory compliance, enterprise risk management, internal controls management, and operation and information technology (IT) audits. Further, it provides supply chain management services comprising strategy development, procurement and supplier management, logistics and materials management, supply chain planning and forecasting, and unique device identification compliance; and human capital services, including change management, organization development and effectiveness, compensation and incentive plan strategies, and optimization of human resources technology and operations. Additionally, the company offers legal and regulatory supporting services for commercial transactions, global compliance initiatives, law department operations, and law department business strategies and analytics. It also provides policyIQ, a proprietary cloud-based governance, risk, and compliance software application. The company was formerly known as RC Transaction Corp. and changed its name to Resources Connection, Inc. in August 2000. Resources Connection, Inc. was founded in 1996 and is headquartered in Irvine, California.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating Research Coverage. We are initiating research coverage of Resources Connection, Inc. (RGP) with an Outperform rating and a $15 price target. We view RGP as a disruptor in the rapidly evolving management consulting field focused on improving outcomes for both its consulting clients as well as staff, be it internal or external. 

Who Is Resources Connection? Resources Connection is a global consulting firm focused on project execution services that power clients’ operational needs and change initiatives utilizing on-demand, experienced, and diverse talent. As a next-generation human capital partner, RGP specializes in co-delivery of enterprise initiatives typically precipitated by business transformation, strategic transactions, or regulatory change.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Aurania Resources (AUIAF) – Sustaining Positive Momentum; Upgrading to Outperform

Posted on by cpereira@noblefcm.com


Wednesday, May 29, 2024

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Raising our rating to Outperform. With two tranches of its recently announced equity financing closed, Aurania is well positioned to execute its 2024 exploration program and secure a joint venture or strategic partner to advance its project in Ecuador. To date, Aurania’s exploration and drilling activities have underscored the project’s rich mineral potential for epithermal gold, porphyry copper, sediment-hosted copper-silver and silver-zinc mineralization.

Private placement financing. Aurania Resources closed the first and second tranches of its private placement of up to 20,000,000 units for gross proceeds of up to C$4,000,000. In aggregate, 15,094,112 units were sold at a price of C$0.20 per unit for total gross proceeds of C$3,018,822.40. The company expects to close the third and final tranche soon. The proceeds will fund exploration and target refinement at the Kuri-Yawi target area in Ecuador, along with general working capital needs.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Charging Ahead: How U.S. Tariffs on Chinese EVs Will Impact the Market

Posted on by slightbourne@noblecapitalmarkets.com

The United States government has fired a major salvo in the escalating electric vehicle (EV) battleground with China, slapping heavy tariffs on Chinese EV imports as well as key battery materials and components. While the move aims to protect American jobs and manufacturers, it carries significant implications for automakers, suppliers, and investor portfolios on both sides of the Pacific.

At the center of the new trade barriers is a 100% tariff on Chinese-made EVs entering the U.S. market. The administration has also imposed 25% duties on lithium-ion batteries, battery parts, and critical minerals like graphite, permanent magnets, and cobalt used in EV production.

For American automakers like Tesla, General Motors, and Ford, the tariffs could provide a substantial competitive advantage on home soil. By erecting steep import costs on Chinese EVs, it makes their domestically produced electric models immediately more price competitive versus foreign rivals. This pricing edge could help ramp up EV sales for Detroit’s Big Three as they work to gain traction in this burgeoning market.

The tariffs represent a major headache for Chinese automakers like BYD that have ambitions to crack the lucrative U.S. EV market. BYD and peers like Nio have been counting on American sales to drive their global expansion efforts. The 100% tariff makes their EVs essentially uncompetitive on price compared to domestic alternatives.

However, the calculus could change if Chinese EV makers ramp up battery production and vehicle assembly closer to U.S. shores. BYD has already established a manufacturing footprint in Mexico. If more production is localized in North America, Chinese brands may be able to circumvent the duties while realizing lower logistics costs.

The impacts extend beyond just automakers. Battery material suppliers and lithium producers could face production cuts and lower pricing if Chinese EV demand softens due to fewer exports heading stateside. Major lithium producers like Albemarle and SQM saw shares dip as the tariff news increased global oversupply fears.

But if U.S. electric vehicle adoption accelerates in response to the import barriers, it could create new demand for lithium and other battery materials from domestic sources, analysts note. North American miners and processors may emerge as beneficiaries as automakers look to localize their supply chains.

Of course, trade disputes cut both ways. There are risks that China could retaliate against major U.S. exports or American companies operating in the country. That creates potential headwinds for a wide range of U.S. multinationals like Apple, Boeing, and Starbucks that rely on Chinese production and consumption. Any tit-for-tat actions could ripple across the global economy.

The levies also raise costs across EV supply chains at a vulnerable time. With inflation already depressing consumer demand, pricier batteries and components could curb the pace of electrification both in the U.S. and globally if passed along to car buyers. Conversely, domestic automakers have leeway to absorb higher input expenses to gain market share from Chinese imports.

With EV competition heating up between the world’s two largest economies, investors will need to scrupulously analyze potential winners and losers from the unfolding trade battle across the electric auto ecosystem. In the near-term, the tariffs appear to boost American legacy automakers while putting China’s crop of upstart EV makers on the defensive. Global battery and mineral suppliers face an uncertain shake-up.

Over the longer haul, costs, capital outlays, production geography, and consumer demand dynamics will ultimately determine the fallout’s enduring market impacts. The new levies represent a double-edged sword potentially accelerating the EV transition in the U.S. while fracturing previously integrated cross-border supply lines.

Prudent investors should weigh both the risks and opportunities across the entire EV value chain. While headline-grabbing, tariffs alone won’t determine winners and losers in the seismic shift to electric mobility taking shape globally. Proactively adjusting portfolios to the changing landscape will be crucial for optimizing exposures.

Want small cap opportunities delivered straight to your inbox?

Channelchek’s free newsletter will give you exclusive access to our expert research, news, and insights to help you make informed investment decisions.

Get Instant Access

Release – Salem Media Group Announces New West Region Digital Sales Director Christian Kligora

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on SALM

CAMARILLO, Calif.–(BUSINESS WIRE)– Salem Media Group, Inc. (OTCQX: SALM) announced Christian Kligora as the new West Region Digital Sales Director on its digital marketing firm, Salem Surround.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523736968/en/

Christian Kligora (Photo: Business Wire)

Christian brings a wealth of digital marketing and operational experience to Salem with his work for Marketron where he served in an executive leadership position driving business development. Prior to that, Christian had over a decade of building teams and driving revenue and operational growth for Gannett’s Local IQ and its predecessor, ReachLocal where he oversaw the growth and management of many local and regional offices.

Jon Latzer, Vice President, General Manager of Salem Surround, said, “Christian Kligora is a generational find and will help Salem Surround achieve both revenue growth and help with operational efficiencies. We are excited to have him join our expanding team while leading our Western Region to new heights of success.”

“I’m excited to join the fantastic team at Salem Media,” said Christian Kligora. “Joining Salem represents a unique opportunity to contribute to a media landscape that values integrity, innovation, and impact. I am eager to partner with our linear/digital sales teams to explore innovative ways to connect with our audience.”

Christian is based in Denver where he lives with his wife Angela.

ABOUT SALEM MEDIA GROUP:

Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.com.

Evan D. Masyr
Executive Vice President and Chief Financial Officer
(805) 384-4512
evan@salemmedia.com

Source: Salem Media Group, Inc.

Released May 28, 2024

Release – Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

Posted on by slightbourne@noblecapitalmarkets.com

Research News and Market Data on OCGN

MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024.

“Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting blindness diseases—both rare and those affecting millions—in clinical trials,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “This ranking signifies the value of our pipeline, including the recently initiated Phase 3 liMeliGhT clinical trial of OCU400 for broad retinitis pigmentosa, and robust growth strategy, supporting our efforts to enable long-term shareholder value, garner significant visibility of Ocugen within the investment community, and broaden our shareholder base.”

The annual Russell 3000® Index reconstitution measures the performance of the largest 3,000 U.S. companies representing approximately 96% of the investable U.S. equity market as of Tuesday, April 30.

Membership in the U.S. Russell 3000® remains in place for one year and means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell’s U.S. indexes serve as the benchmark for about $10.5 trillion in assets as of the close of December 2023. Russell indexes are part of FTSE Russell, a leading global index provider.

About FTSE Russell:
FTSE Russell is a leading global provider of benchmarking, analytics, and data solutions for investors, giving them a precise view of the market relevant to their investment process. A comprehensive range of reliable and accurate indexes provides investors worldwide with the tools they require to measure and benchmark markets across asset classes, styles, or strategies.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products, and index-based derivatives.

FTSE Russell is focused on applying the highest industry standards in index design and governance, employing transparent rules-based methodology informed by independent committees of leading market participants. FTSE Russell fully embraces the IOSCO Principles, and its Statement of Compliance has received independent assurance. Index innovation is driven by client needs and customer partnerships, allowing FTSE Russell to continually enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit: https://www.lseg.com/en/ftse-russell.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company’s expected inclusion in the Russell 3000 ® Index, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that changes may be made to the preliminary Russell reconstruction lists prior to finalization, that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com

Release – Orion Group Holdings Set to Join the Russell 3000® Index

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on ORN

HOUSTON, May 28, 2024 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective after the US market opens on July 1, 2024, according to a preliminary list of additions posted May 24, 2024.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

“Being included in the Russell Index is an important milestone for Orion and reflects the significant progress we have made transforming the business throughout 2023. Our inclusion in the Russell Index should help expand investor awareness, increase institutional ownership, and provide additional liquidity in our stock,” said Travis Boone, Chief Executive Officer of Orion Group Holdings, Inc. “This milestone was achieved during an exciting time for Orion. With a strong foundation of operational discipline, a vastly improved business development team and a healthy balance sheet, we have set the Company up for success and are focused on driving growth for the remainder of 2024 and beyond.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of December 2023, about $10.5 trillion in assets are benchmarked against Russell’s US indexes, which belong to FTSE Russell, a prominent global index provider.

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Hawaii, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design and specialty services. Its concrete segment provides turnkey concrete construction services including place and finish, site prep, layout, forming, and rebar placement for large commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas with regional offices throughout its operating areas. The Company’s website is located at: https://www.oriongroupholdingsinc.com.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the “safe harbor” provisions of Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, of which provisions the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release, and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, gross profit, EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, or cash flow, including to service debt or maintain compliance with debt covenants, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward-looking statements also include project award announcements, estimated project start dates, anticipated revenues, and contract options which may or may not be awarded in the future. Forward-looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints, and any potential contract options which may or may not be awarded in the future, and are at the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. Considering these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise, except as required by law.

Please refer to the Company’s 2023 Annual Report on Form 10-K, filed on March 1, 2024 which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Contacts:
Financial Profiles, Inc.
Margaret Boyce 310-622-8247
orn@finprofiles.com 

Russell Reconstitution 2024: The Ultimate Guide to This Year’s Index Shake-Up

Posted on by slightbourne@noblecapitalmarkets.com

The annual Russell reconstitution is one of the biggest events in the investing world, shaping the composition of the widely followed Russell indexes, including the influential Russell 2000 and Russell 3000 indexes. This comprehensive process ensures these indexes accurately represent various U.S. market segments by reflecting changes in company market capitalizations and characteristics.

What is the Russell Reconstitution?
The Russell reconstitution is an annual rebalancing process where all Russell equity indexes undergo a complete overhaul. During reconstitution, the index provider FTSE Russell rebuilds the Russell indexes from the ground up based on new data on eligible stocks’ market caps, trading volumes, and other criteria.

This vital event maintains the integrity of Russell indexes as accurate benchmarks by updating their holdings to reflect the current landscape of the U.S. stock market. Reconstitution allows companies that have grown or shrunk in value to be properly represented in the appropriate Russell indexes.

The Importance of the Russell 3000 Index
A major focus of the reconstitution is the Russell 3000 Index, considered one of the leading benchmarks for the overall U.S. equity market. This index aims to capture 98% of U.S. stocks by market cap.

On May 24, 2024, FTSE Russell published its annual reconstitution updates, revealing notable new additions to the Russell 3000 like Ocugen, Eledon Pharmaceuticals, NN Inc., and Bitcoin Depot. Such changes highlight how reconstitution allows the index to evolve with the market.

The Closely Watched Russell 2000 Index
Another keenly watched Russell index is the small-cap Russell 2000, which tracks the smallest 2,000 companies in the Russell 3000 by market cap. This index is considered a leading benchmark for small-cap U.S. stocks.

During reconstitution, companies can move in or out of the Russell 2000 based on changes to their market capitalization or investment style exposures like value vs growth. This rebalancing ensures the Russell 2000 precisely represents today’s small-cap universe.

IPO Additions Throughout the Year
In addition to the annual reset, FTSE Russell regularly adds eligible IPO stocks to its indexes on a quarterly basis. This allows newly public companies to quickly enter major benchmarks like the Russell 3000 instead of waiting for reconstitution.

Russell’s IPO treatment distinguishes between fully underwritten IPOs and partial or “best efforts” public offerings when determining appropriate share weights and eligibility.

Rebalancing Drives Major Trading Activity
Russell reconstitution is a major trading event, as index funds and ETFs tracking Russell benchmarks must rebalance their portfolios to match updated index constituents and weightings.

Estimates suggest hundreds of billions in assets follow the Russell benchmarks, meaning their reconstitution announcements can trigger massive shifts in demand for newly added or removed stocks.

Following Russell’s Transparent Methodology
FTSE Russell’s reconstitution process follows an objective, rules-based methodology spelled out in publicly available documentation. Key eligibility factors include:

  • Trading on eligible U.S. stock exchanges
  • Meeting minimum price, market cap, and liquidity thresholds
  • Sufficient public share float and voting rights
  • Eligible corporate structures like public operating companies

Staying on top of Russell’s transparent reconstitution rules allows investors to understand how index changes may impact their portfolios and positions.

The Russell Reconstitution’s Continuing Impact
As indexes like the Russell 3000 continue gaining prominence as core portfolio benchmarks, Russell reconstitution’s influence grows. The 2024 event reinforces the Russell indexes’ role in definitively capturing U.S. market performance by surgery evolving index holdings to match current realities.

Whether reallocating client assets, developing new index funds, or simply understanding market composition changes, the 2024 Russell reconstitution guide will prove essential reading for investors. Follow this yearly event closely, as it shapes the benchmarks driving U.S. equity allocations for years to come.

Upcoming 2024 Russell Reconstitution Schedule

Friday, May 31st, June 7th, 14th, and 21st – Preliminary membership lists (reflecting any updates) posted to the FTSE Russell website after 6PM US eastern time.

Monday, June 10th – “Lock-down” period begins with the updates to reconstitution membership considered to be final.

Friday, June 28th – Russell Reconstitution is final after the close of the US equity markets.

Monday, July 1st – Equity markets open with the newly reconstituted Russell US Indexes.

Bitcoin Mining Showdown: Riot Platforms’ Power Play for Bitfarms

Posted on by slightbourne@noblecapitalmarkets.com

In a bold move that could significantly reshape the cryptocurrency mining industry, Riot Platforms Inc. has made an unsolicited offer to acquire rival Bitcoin miner Bitfarms Ltd. for $950 million. This acquisition bid, which includes both cash and stock, values Bitfarms at $2.30 per share, a 20% premium over its pre-offer trading price. Riot’s aggressive strategy is driven by recent industry dynamics and Bitfarms’ internal challenges, and it has the potential to profoundly impact the Bitcoin mining landscape.

Riot Platforms, already a major player in the Bitcoin mining sector, has taken a 9.25% stake in Bitfarms, making it the largest shareholder. This move follows Bitfarms’ management turmoil, including the firing of interim CEO Geoffrey Morphy, who is now suing the company for $27 million in damages. Riot’s initial offer, made on April 22, was rejected by Bitfarms’ board without substantive dialogue. Undeterred, Riot plans to call a shareholder meeting to appoint new independent directors, signaling a clear intention to influence Bitfarms’ strategic direction.

The proposed acquisition highlights a significant trend in the Bitcoin mining sector: consolidation. This trend has been accelerated by the recent Bitcoin “halving,” an event that occurs approximately every four years and cuts the rewards miners receive for validating transactions by 50%. This reduction in rewards tightens margins and pushes miners to either scale operations or seek consolidation to maintain profitability.

For Riot, absorbing Bitfarms would create the largest Bitcoin miner globally, based on projected computing power growth. This expansion would significantly enhance Riot’s Bitcoin production capabilities, positioning it alongside industry giants like Marathon Digital Holdings Inc. and CleanSpark Inc. The increased scale and capacity would provide Riot with greater negotiating power, more efficient operations, and improved resilience against market fluctuations and rising energy costs.

Riot’s pursuit of Bitfarms sends a clear message to other players in the Bitcoin mining space: scale is essential for survival and success in the post-halving era. Smaller miners, already struggling with reduced revenues and limited access to capital, may find it increasingly challenging to compete against larger, resource-rich companies. This could trigger a wave of mergers and acquisitions as miners seek to consolidate resources, optimize operations, and leverage economies of scale.

For instance, Bitcoin miner Stronghold Digital Mining Inc. is already exploring strategic alternatives, including a potential sale. As the industry adapts to the new economic realities imposed by the halving, more companies might follow suit, either by seeking mergers or becoming acquisition targets themselves.

The consolidation trend among Bitcoin miners has broader implications for the cryptocurrency industry. Firstly, it could lead to increased centralization of mining power, potentially raising concerns about the decentralization ethos of Bitcoin. However, it could also result in more efficient and stable mining operations, reducing the risk of disruptions and enhancing the overall security and reliability of the Bitcoin network.

Moreover, large-scale miners like Riot, with significant resources and capacity, are better positioned to adopt sustainable practices and negotiate favorable energy contracts, potentially addressing some of the environmental criticisms faced by the industry.

Riot Platforms’ bid to acquire Bitfarms marks a pivotal moment in the evolution of Bitcoin mining. This strategic move underscores the importance of scale in navigating the post-halving landscape and sets the stage for further consolidation in the industry. For investors and stakeholders in the cryptocurrency space, this development highlights the dynamic and competitive nature of Bitcoin mining, where agility, resources, and strategic vision are key to thriving in an ever-evolving market. As the industry continues to mature, the actions of major players like Riot will undoubtedly shape the future of cryptocurrency mining and its role within the broader financial ecosystem.

Take a moment to take a look at Bit Digital, a large-scale bitcoin mining business with operations across the U.S. and Canada.

Release – YS Biopharma Announces Name Change to LakeShore Biopharma

Posted on by aweinsoff@channelchek.com

GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ — YS Biopharma Co., Ltd. (Nasdaq: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced it is changing its legal name from “YS Biopharma Co., Ltd.” to “LakeShore Biopharma Co., Ltd”.

   

Dr. David Shao, Director, President, Co-Chief Executive Officer, and Chief Business Officer of the Company, commented, “We have decided to change our company name to LakeShore Biopharma to align with our global market positioning and international brand image. This change marks one of the first steps for us to expand our market reach, and we are eager to move forward and drive success under our new company name.”

The name change and trading symbol change will not affect any rights of shareholders or the Company’s operations and financial position. The Company’s ordinary shares and warrants will continue to be listed on the Nasdaq. Effective with the opening of the trading day on May 28, 2024, the ticker symbol of the Company’s ordinary shares and warrants will change from “YS” to “LSB” and from “YSBPW” to “LSBPW”, respectively. There is no action required by the Company’s current shareholders with respect to the company name or ticker symbol changes. The Company’s CUSIP will not change in connection with the name change.

About LakeShore Biopharma (formerly known as YS Biopharma)

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharma.com.

Investor Relations Contact

Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-announces-name-change-to-lakeshore-biopharma-302155079.html

SOURCE